|Tested species reactivity||Human, Non-human primate, Pig, Rabbit, Rat|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant protein encoding human chromogranin A|
|Storage buffer||PBS, pH 7.6, with 0.2% BSA|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:400|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 2 publications below|
PA5-16685 targets Chromogranin A in IHC (P) applications and shows reactivity with Human, Non-human primate, Porcine, Rabbit, and Rat samples.
The PA5-16685 immunogen is recombinant protein encoding human chromogranin A.
Chromogranin A (a protein of 439 amino acid which is encoded on chromosome 14) is present in neuroendocrine cells throughout the body, including the neuroendocrine cells of the large and small intestine, adrenal medulla and pancreatic islets. It is an excellent marker for carcinoid tumors, phenochromocytomas, paragangliomas, and other neuroendocrine tumors. Coexpression of chromogranin A and neuron specific enolase (NSE) is common in neuroendocrine neoplasms. This antibody is excellent for formalin-fixed, paraffin-embedded tissues with no special pretreatment.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Identification of novel target proteins in sebaceous gland carcinoma.
PA5-16685 was used in immunohistochemistry to identify novel therapeutic target proteins in sebaceous gland carcinoma
|Erovic BM,Al Habeeb A,Harris L,Goldstein DP,Kim D,Ghazarian D,Irish JC||Head and neck (35:642)||2013|
Prognostic and predictive markers in medullary thyroid carcinoma.
PA5-16685 was used in immunohistochemistry to identify markers with progniostic and predictive value in patients with medullary thyroid cancer
|Erovic BM,Kim D,Cassol C,Goldstein DP,Irish JC,Asa SL,Mete O||Endocrine pathology (23:232)||2012|